Figure 6
From: Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression
Prognostic value of SNAT1 and p-Akt expression in patients with breast cancer. (A) Survival durations were significantly worse in patients with positive expression of SNAT1 (median survival, 48.8 mo) than in those with negative expression of SNAT1 (median survival, 50.8 mo; P= 0.025). (B) No significant difference of survival durations were found between patients with positive expression of p-Akt (median survival, 49.1 mo) and those with negative expression of p-Akt (median survival, 50.3 mo; P= 0.167).